Merrill Lynch Greater Europe IT PLC
17 May 2005
MERRILL LYNCH GREATER EUROPE INVESTMENT TRUST plc
All information is at 30 April 2005 and unaudited.
Performance at month end with net income reinvested
One Three Since launch
Month Months (20Sep04)
Net asset value -3.9% -1.8% 9.4%
Share price -3.2% -0.2% 5.5%
FTSE World Europe ex UK -4.1% -1.9% 7.9%
Sources: Merrill Lynch Investment Managers and Datastream.
At month end
Net asset value: 109.45p Includes net revenue of 1.01p
Share price: 105.50p
Discount to NAV: 3.6%
Gearing: 3.6%
Net yield: N/A
Total assets: £185.1m
Ordinary shares in issue: 164,841,285
Benchmark
Sector Analysis Total Assets (%) Index (%) Country Analysis Total Assets (%)
Financials 33.8 30.5 France 26.0
Cyclical Services 10.4 6.2 Germany 16.7
Non Cyclical Consumer Goods 11.4 15.7 Switzerland 14.4
Resources 9.5 9.6 Scandinavia 7.6
Basic Industries 7.3 7.1 Italy 7.4
Non Cyclical Services 5.9 1.3 Sweden 4.9
Utilities 4.9 6.5 Spain 3.7
Telecoms 4.6 8.2 Russia 3.5
Capital Goods 4.2 5.5 Ireland 3.2
Cyclical Consumer Goods 3.2 4.5 Belgium 2.8
Technology 2.8 4.9 Netherlands 2.4
Other Investments 2.4 - Israel 2.3
Net Current Liabilities (0.4) - Turkey 1.9
Greece 1.6
Portugal 0.9
Poland 0.9
Other Countries 0.2
Net Current Liabilities (0.4)
----- ----- -----
100.0 100.0 100.0
----- ----- -----
Ten Largest Equity Investments
Company % of Total Assets Country of Risk
Total 4.6 France
Sanofi-Aventis 3.4 France
UBS 3.4 Switzerland
Roche Holdings 2.7 Switzerland
Capitalia 2.5 Italy
Ericsson 2.5 Sweden
AXA 2.5 France
Credit Suisse 2.4 Switzerland
Societe Generale 2.4 France
Carrefour 2.2 France
----
Total 28.6
----
Commenting on the markets, James Macmillan, representing the Investment Manager
noted:
Equity markets declined for a second consecutive month in April 2005 with the
FTSE World Europe ex UK and MSCI Emerging Europe down 4.1% and 3.4% in sterling
terms respectively. Whilst investors were encouraged by the retreating oil
price, there was considerable concern about evidence of sharply decelerating
global economic growth. Another widely anticipated 0.25% increase in US short
term interest rates (pencilled in for early May) did little to alter the market
expectation of further monetary tightening in the US.
The Company's NAV returned -3.9% during the month, outperforming the reference
benchmark index. During the month stock selection was slightly positive with
sector selection having a negative effect on performance. The Company benefited
from exposure to Emerging Europe, with a number of holdings in Israel, Russia
and Turkey outperforming.
In light of a rising uncertainty the more defensive segments of the market did
best in April with Pharmaceuticals (+4%), Real Estate (+2%), Tobacco (+1%),
Other Utilities (+1%), Health (-2%) and Electricity (-2%) all posting above
average returns. Against the trend IT Hardware stocks also 'outperformed' (-1%)
following a run of poor performance in previous months. Most cyclical sectors
did poorly with Steel (-12%), Leisure & Hotels (-9%), Electronic & Electrical
Equipment (-9%), Forestry & Paper (-8%), Household Goods & Textiles (-7%) and
Engineering & Machinery (-7%) clearly underperforming. The Life Assurance (-7%)
and Insurance (-7%) sectors also suffered because of their perceived exposure to
equity markets.
During the period the best performing stocks were Capitalia which rose after
good results and bid speculation within the Italian banking sector, Roche up
after positive news flow on its key cancer drug, and Fortum which rose ahead of
the IPO of its oil refining business Neste Oil. Other strong performers were
Emporiki Bank of Greece, Sanofi-Aventis and Statoil. Stocks that detracted from
performance were engineering consultant Altran Technologies down after the
company missed second half margin targets, Prokom Software due to corporate
governance issues, and steel producer Arcelor due to concerns that the steel
cycle may have peaked. Other poor performers were car manufacturer Porsche,
Ahold and and Kuoni.
During March the Company purchased holdings in Swiss Investment bank Credit
Suisse, Healthcare company Fresenius and spirits producer Pernod Ricard. This
was partly funded by reducing exposure to the IT sector by selling Nokia and
Altran Technologies.
The main bias of the Company is towards financials and defensives at the expense
of cyclicals and growth. This is reflected at the sector level through banks,
diversified financials, energy, telecoms and pharmaceuticals. The main country
exposures are in France, Germany and Switzerland. Our exposure to Emerging
Europe was 10.1% and the Trust ended the month with a net market exposure of
103.6%.
The macroeconomic newsflow was generally soft in April. Recent surveys suggest
that business confidence has faltered in Continental Europe as a result of high
energy prices and a weak US Dollar. Despite some bright spots in the periphery
countries such as Spain and Ireland, domestic demand across much of Continental
Europe continues to be weak as households suffer from persistently high
unemployment and weak purchasing power. GDP growth in the Eurozone was reported
to have run at 0.5% quarter on quarter in Q1 with little improvement in
prospect. The consensus view is that economic growth will remain below its
potential rate for the foreseeable future. As a result few observers expect the
European Central Bank to raise interest rates any time soon.
Latest information is available by typing www.mlim.co.uk/its on the internet,
'MLIMINDEX' on Reuters, 'MLIM' on Bloomberg or '8800' on Topic 3 (ICV terminal).
17 May 2005
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.